Mizuho Maintains Buy on ADMA Biologics, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Anthony Petrone has reaffirmed a Buy rating on ADMA Biologics (NASDAQ:ADMA) and increased the price target from $7 to $9, indicating a positive outlook on the company's stock.
January 22, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Anthony Petrone maintains a Buy rating on ADMA Biologics and raises the price target from $7 to $9, suggesting a bullish stance on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and can positively influence investor sentiment, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100